Search results
The goal is to understand the regulatory history and compliance of a company's products and research before entering into an agreement. This document discusses important areas of due diligence for companies considering partnering or acquiring another company's pharmaceutical or biologic products.
Emerging Life Sciences Companies Deskbook: Author: Morgan, Lewis & Bockius: Edition: 2: Publisher: Morgan, Lewis & Bockius, 2008 : Export Citation: BiBTeX EndNote RefMan
Showing all editions for 'Emerging life sciences companies deskbook' Sort by: Format; All Formats (2) Print book (2) Refine Your Search; Year. 2008 (1) 2006 (1) Language. English; Displaying Editions 1 - 2 out of 2: Select All: Clear All: Save ... You can easily create a free account.
12 Emerging Life Sciences Companies Deskbook The following is a detailed outline of various issues to consider when spinning out a new venture. Reasons for Spinning Out A. To free the Company from its parent’s resource allocation and planning decisions and other constraints that may not be consistent with its health and growth
Joe Daniels, the co-chair of Nelson Mullins' Emerging Companies practice, discusses what makes up his practice and what goes in to helping it succeed, emphas...
In order to overcome the challenges that face a life sciences company such as yours in a merger or acquisition, you need to understand the differences between private companies’ and public companies’ reasons for entering into a merger or acquisition, the different structures for private and
There is increased scope and significance of FDA regulatory issues/safety concerns; new pricing/reimbursement issues; and an expansion of the number of, and competition for, life science companies. The following outline sets forth many of such issues.
